This month’s list of new technology, partnerships, and other announcements includes items from ObvioHealth, Datavant, HumanFirst, and other industry players.
The pharmaceutical company reports studies have demonstrated the main protease inhibitor of Paxlovid maintains in vitro efficiency against the variant.
A leader from health tech solutions company Vytal examines supply chain challenges faced in the pharmaceutical field and shares some potential solutions.
A representative from IFF Pharma Solutions talks about significant challenges in drug development and improvements the industry can implement to overcome them.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The pharmaceutical company has announced GMP-related challenges with a manufacturer contracted to fill syringes for Wegovy pens headed to the US market.
A leader from the company discusses how advanced analytical tools can be put to work to help tackle adverse event case processing and compliance issues.
A leader from the R&D tech provider discusses the obstacles faced by drug development professionals in recent months, and ways they rose to the occasion.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Stevanato Group is showcasing its SG Alina disposable, variable-dose pen injector platform, available with customizable features, at CPhI Worldwide 2021.
This capsule of industry news features Amcor, High Purity New England, MG America, and other firms offering packaging and labeling products and services.
This month’s announcements of programs, names, appointments, hires, and other happenings includes items from Emmes, Science 37, Cerner and other companies.
